Evidence map›Paper›PMID 20729387›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2010

Antenatally administered PPAR-gamma agonist rosiglitazone prevents hyperoxia-induced neonatal rat lung injury.

Virender K Rehan, Reiko Sakurai, Julia Corral, Melissa Krebs, Basil Ibe, Kaori Ihida-Stansbury, John S Torday

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Antenatal PPAR-γ agonist pioglitazone stimulates fetal lung maturation equally in males and females.American journal of physiology. Lung cellular and molecular physiology · 2020
    Article
  5. Review
  6. Review
  7. Review
  8. Oxidative stress diseases unique to the perinatal period: A window into the developing innate immune response.American journal of reproductive immunology (New York, N.Y. : 1989) · 2018
    Review
  9. Article
  10. Emerging Clinical Benefits of New-Generation Fat Emulsions in Preterm Neonates.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2017
    Review
  11. Article
  12. Review
  13. Review
  14. PPAR-γ agonist rosiglitazone reverses perinatal nicotine exposure-induced asthma in rat offspring.American journal of physiology. Lung cellular and molecular physiology · 2015
    Article
  15. Article
  16. Beyond building better brains: bridging the docosahexaenoic acid (DHA) gap of prematurity.Journal of perinatology : official journal of the California Perinatal Association · 2015
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Virender K RehanDept. of Pediatrics, Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, David Geffen School of Medicine at UCLA, 1124 West Carson St., Torrance, CA 90502, USA. vrehan@labiomed.org
Reiko Sakurai
Julia Corral
Melissa Krebs
Basil Ibe
Kaori Ihida-Stansbury
John S Torday
University of California, Los Angeles · USLos Angeles Medical Center · USThe Lundquist Institute · USUniversity of Pennsylvania · US

Funding

HORMONAL REGULATION OF LUNG DEVELOPMENT;PTHrP BIOLOGYR01HL055268 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI TORDAY, JOHN STEVEN · 1997 to 2009
$3.3M
PPARgamma Signaling/Lung Fibroblast TransdifferentiationR01HL075405 · NHLBI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2005 to 2009
$1.7M
Fibroblast Cell Signaling in Utero Nicotine-Induced Lung InjuryR01HD051857 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2008 to 2012
$1.7M
A Molecular Approach to Prevent Pulmonary Dysfunction in the Intrauterine GrowthR03HD058948 · NICHD · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI REHAN, VIRENDER K · 2009 to 2010
$137k
NHLBI NIH HHS HL55268NHLBI NIH HHS HL75405NHLBI NIH HHS R01 HL055268NHLBI NIH HHS R01 HL075405NICHD NIH HHS HD058948NICHD NIH HHS HD51857NICHD NIH HHS R01 HD051857NICHD NIH HHS R03 HD058948
6 · The paper itself

Abstract

The physiological development and homeostasis of the lung alveolus is determined by the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) by the interstitial lipofibroblast. We have recently shown (Dasgupta C et al., Am J Physiol Lung Cell Mol Physiol 296: L1031-L1041, 2009.) that PPAR-γ agonists administered postnatally accelerate lung maturation and prevent hyperoxia-induced lung injury. However, whether the same occurs antenatally is not known. The objective of this study was to test the hypothesis that the potent PPAR-γ agonist rosiglitazone (RGZ), administered antenatally, enhances fetal lung maturation and protects against hyperoxia-induced neonatal lung injury. Sprague-Dawley rat dams were administered either diluent or RGZ (3 mg/kg), at late gestation, to determine its effect on lung maturation and on hyperoxia (95% O(2) exposure for 24 h)-induced neonatal lung injury. The lungs were examined for the expression of specific markers of alveolar development (surfactant proteins A and B, cholinephosphate cytidylyltransferase-α, leptin receptor, triglyceride uptake, and [(3)H]choline incorporation into saturated phosphatidylcholine) and injury/repair, in particular, the markers of transforming growth factor-β signaling (activin receptor-like kinase-5, SMAD3, lymphoid enhancer factor-1, fibronectin, and calponin). Overall, antenatal RGZ accelerated lung maturation and blocked the inhibition of alveolar sacculation and septal wall thinning by hyperoxia. RGZ specifically stimulated the development of the alveolar epithelial type II cell, the lipofibroblast, and the vasculature. The increased expression of the transforming growth factor-β intermediates, such as SMAD3 and lymphoid enhancer factor-1, implicated in hyperoxic lung injury, was also blocked by antenatal RGZ treatment. In conclusion, PPAR-γ agonists can enhance fetal lung maturation and can effectively prevent hyperoxia-induced neonatal lung injury.

Indexed as

AnimalsAnimals, NewbornCells, CulturedFemaleFibroblastsHumansHyperoxiaLung InjuryPPAR gammaPregnancyPulmonary AlveoliRatsRats, Sprague-DawleyRosiglitazoneThiazolidinedionesPPAR gammaRosiglitazoneThiazolidinediones

Identifiers

PMID20729387
PMCPMC2980388
OpenAlexW1983131403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.